Navigation Links
Generex Provides Clarification of Facts
Date:6/27/2011

e on a comprehensive strategy to achieve FDA approval of Generex Oral-lyn™.  Today, Dr. Anderson, an independent member of the Generex Board, commented:  "The Company's scientific team is confident that our clinical and regulatory program is designed for success, and we intend to conduct a broader study to include a wider patient population in both type 1 and type 2 diabetes."  The full presentation from the annual meeting of stockholders' is available for viewing on the Generex website at www.generex.com.

Mark Fletcher, Generex President & Chief Executive Officer, stated:  "We have made great strides in establishing  a top notch scientific team at Generex and, as a result, have established a realistic and focused plan to realize success in the future for the largest possible patient population.  The closing of the current Phase III study and the data we obtain from it will further that effort.  Generex Oral-lyn™ has demonstrated efficacy and safety in all of the studies conducted to date."

The June 16 Generex press release stated that the Company's clinical and regulatory plan for Generex Oral-lyn™ will "focus on rapid registration in the North American major markets, with its rapid absorption and sharp peak in plasma insulin concentration mimicking normal insulin secretion, and Generex Oral-lyn™'s short duration of activity reducing the potential for hypoglycemia.  Studies will include a key activity/effect (pharmokinetic/glucodynamic) study using the final formulation and a series of small, well-designed phase 3 studies (potentially conducted as one study with multiple arms)."  Generex management anticipates that these studies will be completed during 2013.  Generex will also focus on studies that will measure Generex Oral-lyn™'s ability to provide metabolic benefits that cannot be achieved with subcutaneously inj
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Announces Results of Annual Stockholders Meeting
2. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
3. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
4. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
5. Generex Announces $3.0 Million Capital Investment
6. Generex Provides Additional Details for October 21st Live Video Webcast
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
9. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
10. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
11. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Brook, NY (PRWEB) August 01, 2014 ... @APDN), a provider of DNA-based anti-counterfeiting technology and product ... August 12, 2014 to discuss its fiscal third quarter ... filed with the SEC by the end of the ... DNA Sciences, Inc. management will host a conference call ...
(Date:8/1/2014)... DUBLIN , Aug. 1, 2014 ... of the "The World Market for Flow ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... instruments that are now an important component of ... advanced diagnostic instruments for cancer diagnostics, but their ...
(Date:8/1/2014)... 1. 2014 As one of the 10 ... Annual Meeting & Clinical Lab Expo is the place ... are introduced to the healthcare world. This year, many ... exhibitors will include the latest diagnostic technology in the ... smartphones and biosensors have enabled the development of "labs-on-a-chip" ...
(Date:8/1/2014)... CHICAGO , Aug. 1, 2014 One ... the rise of personalized medicine, which is the practice ... medical treatments to a patient,s individual biology. Personalized diagnostics—laboratory ... a major role in the lab,s future. This fall, ... will feature the latest science in this exciting field ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3The World Market for Flow Cytometry in IVD Applications 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2
... - Worldwide VELCADE(R) (bortezomib) for Injection sales surpassed $765 ... million in 2007 - ... myeloma, with launch on track for ... (Nasdaq: MLNM ) today reported 2007 non-GAAP net,income of $86.9 million and ...
... Feb. 7 ADVENTRX Pharmaceuticals,Inc. (Amex: ... data from,the Company,s marketing-enabling bioequivalence clinical study ... presentation at the 2008,American Association for Cancer ... 12 - 16, 2008 in San Diego, ...
... Ability to Prevent HIV from Replicating, GAITHERSBURG, ... company developing gene therapies for HIV and genetic,diseases, ... VRX496, a gene,therapy for the treatment of AIDS, ... Infections (CROI) in Boston, MA., "This appears ...
Cached Biology Technology:Millennium Over-Delivers on 2007 Goals and Financial Guidance 2Millennium Over-Delivers on 2007 Goals and Financial Guidance 3Millennium Over-Delivers on 2007 Goals and Financial Guidance 4Millennium Over-Delivers on 2007 Goals and Financial Guidance 5Millennium Over-Delivers on 2007 Goals and Financial Guidance 6Millennium Over-Delivers on 2007 Goals and Financial Guidance 7Millennium Over-Delivers on 2007 Goals and Financial Guidance 8Millennium Over-Delivers on 2007 Goals and Financial Guidance 9Millennium Over-Delivers on 2007 Goals and Financial Guidance 10Millennium Over-Delivers on 2007 Goals and Financial Guidance 11Millennium Over-Delivers on 2007 Goals and Financial Guidance 12Millennium Over-Delivers on 2007 Goals and Financial Guidance 13Millennium Over-Delivers on 2007 Goals and Financial Guidance 14Millennium Over-Delivers on 2007 Goals and Financial Guidance 15Millennium Over-Delivers on 2007 Goals and Financial Guidance 16Millennium Over-Delivers on 2007 Goals and Financial Guidance 17Millennium Over-Delivers on 2007 Goals and Financial Guidance 18ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 2ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 3VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 2
(Date:8/1/2014)... -- Modern humans appear in the fossil record about ... years ago that making art and advanced tools became ... in the journal Current Anthropology finds that ... of testosterone levels at around the same time that ... technological innovation, making art and rapid cultural exchange probably ...
(Date:8/1/2014)... what causes them at the molecular level is even ... created the most detailed map to date of a ... diseases, such as age-related macular degeneration. The high-resolution molecular ... supplies blood and oxygen to the outer retina, itself ... of proteins in different areas of the choroid, the ...
(Date:8/1/2014)... the most diverse families in the ocean today -- ... originated more than 400 million years ago in the ... of its modern members. This Geology study ... online on 25 July 2014, tracks the remarkable evolutionary ... At is origin, the Lucinidae family remained at very ...
Breaking Biology News(10 mins):Society bloomed with gentler personalities and more feminine faces 2A map for eye disease 2Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14
... which cancer cells travel from a tumor site and proliferate ... to cancer patients. According to the National Cancer Institute, most ... Virtually all types of cancer can spread to other parts ... are entrenched in the brain, patients typically have only a ...
... the sensitivity of Australia,s species and ecosystems to climate ... about biodiversity conservation. ,Climate change is likely to ... 2030, lead researcher, CSIRO,s Dr Michael Dunlop said.,By 2070, ... and widespread. Many of the environments our plants and ...
... Researchers at the National Institute of Standards and Technology ... candidate refrigerant fluids with low "global warming potential" (GWP) ... for many decades as well as other desirable ... the most extensive systematic search for a new class ...
Cached Biology News:Fighting melanoma's attraction to the brain 2Major changes needed to protect Australia's species and ecosystems 2New NIST screening method identifies 1,200 candidate refrigerants to combat global warming 2
... The S. pombe Whole Genome ... location analysis of yeast (S. pombe) ... immunoprecipitation (ChIP) with Agilent DNA microarrays. ... reliable binding data with greater true ...
... genomes has allowed the development of the ... The S. enterica Typhimurium (strain LT2) genome ... 4,440 ORFs) and a plasmid, pSLT (93,939 ... have been designed to amplify all putative ...
... own microplate stacker system, offers fast and ... host devices:, , Ultra Evolution , SAFIRE ... and SpectraFluor Plus , LS Series of ... supporting a wide range of detection and ...
... LabX light balance makes your life easier. It ... acquisition and management for one balance. *Instruments supported: ... TOLEDO AX, MX, UMX, AG, XS, XP, PR, SR, ... balances *Job management: ...
Biology Products: